|
Name |
Asperterpene L
|
Molecular Formula | C27H36O9 | |
IUPAC Name* |
methyl (1R,2S,4aS,4bS,10aS)-9-hydroxy-2-[(2S)-2-hydroxy-3-methoxy-2-methyl-3-oxopropanoyl]-2,4b,8,8,10a-pentamethyl-3-methylidene-7,10-dioxo-4,4a,5,6-tetrahydro-1H-phenanthrene-1-carboxylate
|
|
SMILES |
C[C@@]12CCC(=O)C(C1=C(C(=O)[C@]3([C@H]2CC(=C)[C@@]([C@@H]3C(=O)OC)(C)C(=O)[C@@](C)(C(=O)OC)O)C)O)(C)C
|
|
InChI |
InChI=1S/C27H36O9/c1-13-12-14-24(4)11-10-15(28)23(2,3)17(24)16(29)19(30)26(14,6)18(20(31)35-8)25(13,5)21(32)27(7,34)22(33)36-9/h14,18,29,34H,1,10-12H2,2-9H3/t14-,18-,24-,25+,26-,27-/m0/s1
|
|
InChIKey |
KLBQENYQBDKIGM-HLPFSFFKSA-N
|
|
Synonyms |
CHEMBL4216625; Asperterpene L; BDBM50459490
|
|
CAS | NA | |
PubChem CID | 139590119 | |
ChEMBL ID | CHEMBL4216625 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 504.6 | ALogp: | 1.7 |
HBD: | 2 | HBA: | 9 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 144.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 36 | QED Weighted: | 0.334 |
Caco-2 Permeability: | -5.509 | MDCK Permeability: | 0.00006290 |
Pgp-inhibitor: | 0.905 | Pgp-substrate: | 0.515 |
Human Intestinal Absorption (HIA): | 0.04 | 20% Bioavailability (F20%): | 0.024 |
30% Bioavailability (F30%): | 0.832 |
Blood-Brain-Barrier Penetration (BBB): | 0.862 | Plasma Protein Binding (PPB): | 51.88% |
Volume Distribution (VD): | 0.431 | Fu: | 51.17% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.986 |
CYP2C19-inhibitor: | 0.039 | CYP2C19-substrate: | 0.801 |
CYP2C9-inhibitor: | 0.011 | CYP2C9-substrate: | 0.028 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.027 |
CYP3A4-inhibitor: | 0.921 | CYP3A4-substrate: | 0.916 |
Clearance (CL): | 4.69 | Half-life (T1/2): | 0.091 |
hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.296 |
Drug-inuced Liver Injury (DILI): | 0.551 | AMES Toxicity: | 0.052 |
Rat Oral Acute Toxicity: | 0.053 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.389 | Carcinogencity: | 0.539 |
Eye Corrosion: | 0.787 | Eye Irritation: | 0.296 |
Respiratory Toxicity: | 0.977 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003849 | 0.573 | D0H2MO | 0.255 | ||||
ENC002162 | 0.552 | D0X4RS | 0.230 | ||||
ENC005250 | 0.548 | D0W5LS | 0.225 | ||||
ENC003284 | 0.422 | D0Q4SD | 0.222 | ||||
ENC002369 | 0.422 | D02HSB | 0.220 | ||||
ENC002033 | 0.352 | D0F7NQ | 0.219 | ||||
ENC006004 | 0.333 | D08BDT | 0.217 | ||||
ENC004115 | 0.329 | D0O5WP | 0.215 | ||||
ENC005965 | 0.319 | D0G4OD | 0.210 | ||||
ENC001949 | 0.312 | D0G7KJ | 0.209 |